What is the biological heterogeneity of prostate cancer and how does it influence treatment decisions?

Biological Heterogeneity of Prostate Cancer and Treatment Implications

Prostate cancer exhibits profound genomic, phenotypic, and spatial heterogeneity that fundamentally shapes treatment decisions—76% of tumor foci within the same prostate share no common point mutations, and this heterogeneity must be directly addressed through molecular profiling, risk-adapted therapy selection, and recognition that single-biopsy genomic data may miss critical tumor biology. 1

Understanding the Scope of Heterogeneity

Inter-Patient Heterogeneity

• Prostate cancers demonstrate significant variation between patients in histomorphological presentation, molecular architecture, and clinical behavior 2
• Genomic alterations differ by ancestry, with ERG rearrangement, PTEN deletion, and SPOP mutation frequencies varying between Caucasian and African American populations 3
• BRCA1 germline and somatic mutations occur at higher frequency in African American patients, though overall germline pathogenic variant rates are similar across racial groups 3

Intra-Patient Heterogeneity

• Most primary prostate cancers are multifocal, with individual tumor foci being clonally distinct and harboring different driver gene alterations 1, 4
• Only 24% of pairwise-compared tumor foci from the same prostatectomy specimen share any point mutations, and DNA copy number changes are rarely shared across cancer foci 1
• The few shared mutations across foci are seldom in cancer-critical genes 1
• Individual tumors within the same patient display intra-tumor heterogeneity in androgen receptor (AR) expression and other phenotypic markers 2

Spatial and Temporal Heterogeneity

• Single-cell sequencing reveals heterogeneity in tumor-associated epithelial cells, cancer-associated fibroblasts, immune microenvironment composition, and spatial distribution of tumor cells 5
• Metastatic disease typically arises from a single clone but exhibits subclonal heterogeneity at genomic, epigenetic, and phenotypic levels 4

Clinical Impact on Treatment Decisions

Risk Stratification and Active Surveillance

• Tissue-based molecular biomarkers (Decipher, Oncotype Dx, Prolaris, ProMark) should be considered in select men with low-risk or favorable intermediate-risk disease when results combined with clinical factors will affect the surveillance versus treatment decision 3
• These genomic classifiers independently improve prognostic accuracy beyond NCCN risk categories and multivariable clinical models 3
• Multifocality limits genomic information if the most biologically aggressive lesion is missed on biopsy, whereas MRI may miss invisible lesions 3
• For very low-risk disease, MRI provides value in identifying missed index lesions; for favorable intermediate-risk disease, genomic classifiers better assess underlying biologic aggressiveness 3

Metastatic Disease Management

• Germline and somatic genomic testing is essential in metastatic prostate cancer to identify actionable alterations including homologous recombination deficiency, microsatellite instability-high (MSI-H), and CDK12 deficiency 6, 7
• Circulating tumor DNA (ctDNA) may be favored over metastatic biopsy in patients with multiple chronic conditions where biopsy safety/feasibility is limited 3
• Tumor heterogeneity, tumor content, and clonal hematopoiesis of indeterminate potential (CHIP) interference must be considered when interpreting ctDNA results 3

Treatment Intensification Decisions

• Disease characteristics including synchronous versus metachronous metastases and metastatic burden impact therapy intensification decisions in metastatic castration-sensitive prostate cancer 7
• Molecular profiling guides sequential therapy selection in metastatic castration-resistant prostate cancer, including AR pathway inhibitors, chemotherapy, radiopharmaceuticals, and targeted therapies 7

Critical Pitfalls and Limitations

Sampling Limitations

• Single-biopsy genomic profiling may fail to capture the most aggressive clone due to multifocality—information from all tumor foci is necessary for valid conclusions about genomic alterations 1
• Standard clinical trials often exclude patients with comorbidities, limiting applicability of genomic testing evidence to real-world heterogeneous populations 3

Therapy-Induced Plasticity

• AR-positive prostate cancer cells can transform into AR-negative cells under therapeutic pressure 2
• Prostate adenocarcinomas may switch lineage identity to neuroendocrine-like tumors, conferring resistance to AR-targeting therapies 2
• Both intrinsic heterogeneity and induced plasticity must be targeted with combinatorial approaches for enduring efficacy 2

Evidence Gaps

• Routine use of molecular biomarkers is not recommended due to lack of prospective data demonstrating improvement in quality of life, metastasis risk, or mortality 3
• No comparative data exist to determine which genomic classifier is most accurate 3
• Limited data support specific risk thresholds provided on individual testing reports 3
• Underrepresentation of African American patients (<5-10%) in PARP inhibitor and checkpoint inhibitor trials limits understanding of racial variation in treatment response 3

Practical Implementation Strategy

For Localized Disease

• Use validated molecular biomarkers only when results combined with clinical factors will change management decisions 3
• Consider genomic testing in high-volume Grade Group 1, favorable intermediate-risk, or situations where genomic data strongly influences surveillance versus treatment choice 3
• Combine MRI and genomic assessment in select cases—MRI followed by targeted biopsy, then genomic evaluation of the most suspicious lesion 3

For Advanced Disease

• Perform comprehensive germline and somatic genomic testing in all metastatic cases to identify actionable alterations 3, 6
• Consider ctDNA when metastatic biopsy poses safety concerns, but account for confounding factors including concurrent hematologic conditions and inflammatory processes 3
• Use molecular profiling to guide therapy sequencing and identify patients warranting treatment escalation 8, 9

Addressing Health Equity

• Recognize that most comprehensive molecular profiling studies included only 13% African American men, limiting generalizability 3
• Equal-access healthcare systems show Black and Hispanic men with nonmetastatic castration-resistant prostate cancer have improved outcomes compared to other groups 3
• Ongoing research into genetic and molecular basis across diverse populations is critical for equitable care 3